![logo](/logos/REPL.webp)
Replimune Group, Inc.
NASDAQ:REPL
10.37 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Replimune Group, Inc. |
Symbool | REPL |
Munteenheid | USD |
Prijs | 10.37 |
Beurswaarde | 708,492,918 |
Dividendpercentage | 0% |
52-weken bereik | 4.92 - 20.05 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Philip Astley-Sparke F.S.A., FSA |
Website | https://www.replimune.com |
An error occurred while fetching data.
Over Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)